Isomorphic Labs 正在通过 AlphaFold 3 的突破性结构预测能力，将药物发现从传统的实验驱动模式转 向 AI 计算驱动的设计模式。该公司不仅实现了分子结构设计的模块化和平台化，更重要的是与礼 来、诺华等顶级药企建立了深度合作，通过真实项目获得实验数据反馈，拿到了数据和收入的双重 正反馈。 这个团队由 DeepMind 的生命科学团队孵化而来，凭借 AlphaFold 3 把蛋白—配体复合体预测精度推 至实验室水准的技术跳变，开始致力于将"小分子设计→虚拟筛选→结构优化"变成可工程化的技术 平台。这使公司有望成为药物研发的"AI Foundry"，在发现阶段可将成本削减 30–40%、周期缩短一 年以上。 今年 3 月公司首次进行了外部融资，获投 6 亿美元，该轮由 Thrive Capital 领投，Google Ventures 参 投，Alphabet 追加跟投。未来 3–5 年，谁能在高难度靶点上做出第一个 AI 设计、实验验证、推进至 临床阶段的候选药物，谁就有机会定义新药发现的游戏规则。Isomorphic Labs 和 AI4Science 领域都 在押注和期待这个临界点的到 ...

张煜介绍称，今年AI赛道呈现出几大趋势，比如大模型从科研模型向产业模型转变，基础的算法算力 向实际的应用迈进。在他看来，AI编程（AI Coding）、AI智能体（AI Agent）和AI硬件将是今年三个 爆发的应用点。 被问及AI创业公司的估值问题，张煜指出，相比起前年和去年，当前估值水平已逐渐回归到理性状 态，大多数的项目与实际估值差距不大。此外，投资向头部公司聚集，例如，过去行业约有100家公 司，其中50家可获得融资，但单笔金额较小，如今可能只有10家能获得投资，但单笔融资规模显著扩 大。（徐苑蕾） "这三个领域可以真正落地，产生商业场景和价值，同时也能真正创造效益，甚至能够盈利。我们观察 了大模型很久，但是没有投资任何一个大模型，而是投资了几个行业模型，覆盖智慧大脑、工业智能、 生命科学蛋白质生成等。"张煜说。 责任编辑：杨赐 在对话中，张煜还重点谈到了人工智能新药研发（AIDD）。他表示，目前大药厂已经认可AI才是未 来。"过去大药厂认为，实验数据和病人是其重要资产，今天他们已经觉得，算法和AI的实验数据可能 会慢慢变成药厂的最重要资产。" 新浪科技讯 5月23日午间消息，第五届BEYOND国际科 ...

Group 1 - The core viewpoint of the articles highlights Sunlight Nuohe's innovative capabilities and growth potential in the pharmaceutical research and development sector, showcasing its integrated business ecosystem of "R&D services + pipeline cultivation + new quality industrial chain" [1] - The company has several innovative products in the R&D phase, covering various therapeutic areas such as autoimmune diseases, pain management, cardiology, central nervous system, oncology, metabolism, and respiratory diseases [1] - Sunlight Nuohe is committed to a dual-driven strategy of "independent innovation + technology transfer," establishing an international standard R&D platform and enhancing its industrial collaboration network to help domestic pharmaceutical companies overcome technical barriers and accelerate import substitution [1] Group 2 - The company is aligning with the trends in biomedicine, leveraging technological breakthroughs, policy support, and market demand, and has established a self-owned peptide innovation drug library screening system [2] - Currently, three innovative drugs have entered clinical stages, including STC007 for postoperative pain, which is in Phase II and soon to enter Phase III, and STC008 targeting cancer cachexia, which has completed Phase IA and is about to start Phase IB [2] - In the field of modified new drug development, the company focuses on sustained-release formulations and high-end formulations, with multiple technology platforms working together to design personalized sustained-release technologies [2] Group 3 - The company has made significant progress in its transdermal delivery research platform, with experience in gel patches and hot melt adhesives, and has partnered with Japan's KANEKA to introduce advanced transdermal patch technology [3] - Sunlight Nuohe is actively exploring the small nucleic acid drug field, which has substantial development potential, and is conducting in-depth research on chemical modifications and delivery systems for small nucleic acid drugs [3] - The company aims to enhance its R&D capabilities by absorbing global cutting-edge technologies and strives to secure a position in the global pharmaceutical market while contributing to the competitiveness of China's pharmaceutical industry [3]

位于中关村朝阳园。 作者 I 杨继云 报道 I 投资界PEdaily 投资界获悉，日前北京市卫生健康委员会官网发布《关于同意抖音集团设立北京爱瑞医院 （待定）项目的批复》的通知，并予以相关指导要求。 | 北京市卫生健康委员会 Beijing Municipal Health Commission | | | ાવ | | | 用户中心 无障碍 北京政务服务网 智能问答 | | --- | --- | --- | --- | --- | --- | --- | | | ○ 搜本网 ● 一网通查 | | | | | | | 首页 要闻动态 政务公开 | | 政务服务 便民服务 | | 政民互动 | 卫生健康文化 | | | 当前位置:政务公开>医疗卫生 | | | | | | | | 北京市卫生健康委员会关于同意抖音集团设立北京爱瑞医院（待定）项目的批复 | | | | | | | | 发布日期：2025-01-16 | | 来源：北京市卫生健康委员会 | | A : A : A | 分享: ( 3) ( 2) | | 这意味着，抖音集团（字节跳动）投资医院项目已成功获批。 至此，字节旗下已拥有多家实体医院——从 ...